An alternative regulatory pathway of the acute phase response: the role of fibroblast-derived interferon-β₂KOJ, A; GORDON, A. H; GAULDIE, J et al.Experientia. 1988, Vol 44, Num 1, pp 9-10, issn 0014-4754Article

Interféron bêta et thyroïde = Beta interferon and thyroidLAARIBI, O; MARRAKCHI, A; MSYAH, L et al.Annales d'endocrinologie. 2006, Vol 67, Num 1, pp 42-44, issn 0003-4266, 3 p.Article

Bioequivalence of Two Subcutaneous Pharmaceutical Products of Interferon Beta 1aDI GIROLAMO, Guillermo; KAUFFMAN, Marcelo A; DIEZ, Roberto A et al.Arzneimittel-Forschung. 2008, Vol 58, Num 4, pp 193-198, issn 0004-4172, 6 p.Article

Immunogenicity of biopharmaceuticals. The european perspectiveSCHELLEKENS, H; CASADEVALL, N.Developments in biologicals. 2003, Vol 112, pp 23-28, issn 1424-6074, 6 p.Article

Activation of the beta interferon promoter by paramyxoviruses in the absence of virus protein synthesisKILLIP, M. J; YOUNG, D. F; PRECIOUS, B. L et al.Journal of general virology. 2012, Vol 93, pp 299-307, issn 0022-1317, 9 p., 2Article

Inhibition of Endogenous Interferon Beta by Neutralizing Antibodies Against Recombinant Interferon BetaSOMINANDA, Ajith; LUNDKVIST, Malin; FOGDELL-HAHN, Anna et al.Archives of neurology (Chicago). 2010, Vol 67, Num 9, pp 1095-1101, issn 0003-9942, 7 p.Article

Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled studyNeurology. 2004, Vol 63, Num 10, pp 1788-1795, issn 0028-3878, 8 p.Article

Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT studyPACHNER, Andrew R; WARTH, John D; PACE, Amy et al.Neurology. 2009, Vol 73, Num 18, pp 1493-1500, issn 0028-3878, 8 p.Article

Model-based analysis of interferon-β induced signaling pathwaySMIEJA, Jaroslaw; JAMALUDDIN, Mohammad; BRASIER, Allan R et al.Bioinformatics (Oxford. Print). 2008, Vol 24, Num 20, pp 2363-2369, issn 1367-4803, 7 p.Article

US FDA-approved disease-modifying treatments for multiple sclerosis: Review of adverse effect profilesGALETTA, Steven L; MARKOWITZ, Clyde.CNS drugs. 2005, Vol 19, Num 3, pp 239-252, issn 1172-7047, 14 p.Article

CHO Cells Adapted to Hypothermic Growth Produce High Yields of Recombinant β-InterferonSUNLEY, Kevin; THARMALINGAM, Tharmala; BUTLER, Michael et al.Biotechnology progress. 2008, Vol 24, Num 4, pp 898-906, issn 8756-7938, 9 p.Article

Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinasesKIESEIER, Bernd C; ARCHELOS, Juan J; HARTUNG, Hans-Peter et al.Archives of neurology (Chicago). 2004, Vol 61, Num 6, pp 929-932, issn 0003-9942, 4 p.Article

High Yields of Monomeric Recombinant β-interferon From Macroporous Microcarrier Cultures Under Hypothermic ConditionsTHARMALINGAM, Tharmala; SUNLEY, Kevin; BUTLER, Michael et al.Biotechnology progress. 2008, Vol 24, Num 4, pp 832-838, issn 8756-7938, 7 p.Article

Desensitization in Interferon-β1a Allergy : A Case ReportKALPAKLIOGLU, Ayse Fusun; KAVUT, Ayse Baccioglu; ERDEMOGLU, Ali Kemal et al.International archives of allergy and immunology. 2009, Vol 149, Num 2, pp 178-180, issn 1018-2438, 3 p.Article

Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients : A comparison of three methods in a large Australasian cohortMCKAY, Fiona; SCHIBECI, Stephen; HEARD, Robert et al.Journal of immunological methods. 2006, Vol 310, Num 1-2, pp 20-29, issn 0022-1759, 10 p.Article

New-onset psoriasis in a patient treated with interferon beta-laLOPEZ-LERMA, I; IRANZO, P; HERRERO, C et al.British journal of dermatology (1951). 2009, Vol 160, Num 3, pp 716-717, issn 0007-0963, 2 p.Article

Induction of β₂-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferationKOHASE, M; HENRIKSEN-DESTEFANO, D; MAY, L. T et al.Cell (Cambridge). 1986, Vol 45, Num 5, pp 659-666, issn 0092-8674Article

Interferon beta-1a overdose in a multiple sclerosis patientFALCONE, Nicola P; NAPPO, Agostino; NEUTEBOOM, Berend et al.The Annals of pharmacotherapy. 2005, Vol 39, Num 11, pp 1950-1952, issn 1060-0280, 3 p.Article

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosisKOCH-HENRIKSEN, N; SORENSEN, P. S; BENDTZEN, K et al.Multiple sclerosis. 2009, Vol 15, Num 5, pp 601-605, issn 1352-4585, 5 p.Article

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episodeGOODIN, D. S; BATES, D.Multiple sclerosis. 2009, Vol 15, Num 10, pp 1175-1182, issn 1352-4585, 8 p.Article

Early treatment and dose optimisation BENEFIT and BEYONDHARTUNG, Hans-Peter.Journal of neurology. Supplement. 2005, Vol 252, Num 3, pp III44-III50, issn 0939-1517Article

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction studyBARBERO, Pierangelo; VERDUN, Elisabetta; BERGUI, Mauro et al.Journal of the neurological sciences. 2004, Vol 222, Num 1-2, pp 13-19, issn 0022-510X, 7 p.Article

Interférons Bêta et sclérose en plaques = Interferons beta and multiple sclerosisLa Revue Prescrire. 2002, Vol 22, Num 225, issn 0247-7750, p. 136Article

Neutralizing antibodies to 500 μg interferon beta-1b: 28-month results of the IDEAS extension trialGOTTESMAN, M. H; FRIEDMAN-UREVICH, S; BOYLAN, E et al.Multiple sclerosis. 2010, Vol 16, Num 1, pp 78-80, issn 1352-4585, 3 p.Article

Interferon-β and lnterferon-λ Signaling Is Not Affected by Interferon-Induced Refractoriness to Interferon-α In VivoMAKOWSKA, Zuzanna; DUONG, Francois H. T; TRINCUCCI, Gaia et al.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 4, pp 1154-1163, issn 0270-9139, 10 p.Article